NAVIGATE x IgM

IgM Purification is Being Solved from First Principles.

NAVIGATE™ IgM Brings Those Doing It Together.

IgM therapeutics are advancing in oncology, immunology, and infectious disease \u2014 but downstream processing has no equivalent to the IgG Protein A platform. Teams are navigating aggregate clearance, size-dependent separation challenges, and HCP profiles without established precedent.

ChromaGenix is developing synthetic affinity ligands designed specifically for IgM \u2014 addressing capture selectivity and purification challenges that conventional resins were not designed to handle. Navigate IgM gives development teams early access to that work.

Challenges Title Here

Several sentences to explain the challenges goes here.

01

Title

Several Sentences of text goes here.

02

Title

Several Sentences of text goes here.

03

Title

Several Sentences of text goes here.

04

Title

Several Sentences of text goes here.

Navigate Cross Link Headline

NAVIGATE cross link

Review our HCP removal platform technical data before your session

Request access to our characterisation data: LC-MS/MS proteomics confirmation, CHO feed performance, HCP clearance profiles and yield recovery figures. Shared under mutual confidentiality before any conversation begins.
request product data

Why wait for better purification tools when you can help shape them?

Join NAVIGATE as an early adopter. Test new resins with your own feedstock, access pre-commercial data, and be first to know when products launch. 

Complete the form and a member of our team will be in touch shortly.

Form Title or Action Step

Put the form here instead of this text box.

Linkedin-in

Chris Major

CEO

Chris is responsible for identifying investment opportunities, assessing strategic fit within the portfolio, and supporting growth-related operational initiatives. A serial entrepreneur with over 20 years of bioprocessing experience, he has deep expertise across upstream and downstream technologies. Prior to BioProcess360, he founded and led the Purolite Bioprocessing division, growing it from zero revenue in 2015 to $80M in six years. The business was acquired by Ecolab (NYSE: ECL) in 2021 for $3.7BN. Earlier, Chris helped pioneer single-use technology at WAVE Bioreactors, later acquired by GE Healthcare (now Cytiva), and held senior roles at GE and Merck Millipore. He holds an MSc in Biotechnology and attended Harvard Business School. Outside work, Chris enjoys biking, paddleboarding, live music, and spending time with his two daughters.